Assessment of Safety of Olaparib in Chinese Patients with Ovarian Cancer in the Real-World Setting

Trial Identifier:	D0817R00082
Sponsor:	AstraZeneca
Start Date:	April 2024
Primary Completion Date:	July 2024
Study Completion Date:	July 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China, Beijing	Beijing, China, 100021

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.